Tags

Type your tag names separated by a space and hit enter

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
J Lipid Res. 2004 Jan; 45(1):174-85.JL

Abstract

Kinetics of apo B and apo AI were assessed in 8 patients with mixed hyperlipidemia at baseline and after 8 weeks of atorvastatin 80 mg q.d. and micronised fenofibrate 200 mg q.d. in a cross-over study. Both increased hepatic production and decreased catabolism of VLDL accounted for elevated cholesterol and triglyceride concentrations at baseline. Atorvastatin significantly decreased triglyceride, total, VLDL and LDL cholesterol and apo B concentrations (-65%, -36%, -57%, -40% and -33%, respectively, P<0.05). Kinetic analysis revealed that atorvastatin stimulated the catabolism of apo B containing lipoproteins, enhanced the delipidation of VLDL1 and decreased VLDL1 production. Fenofibrate lowered triglycerides and VLDL cholesterol (-57% and -64%, respectively, P<0.05) due to enhanced delipidation of VLDL1 and VLDL2 and increased VLDL1 catabolism. Changes of HDL particle composition accounted for the increase of HDL cholesterol during atorvastatin and fenofibrate (18% and 23%, P<0.01). Only fenofibrate increased apo AI concentrations through enhanced apo AI synthesis (45%, P<0.05). We conclude that atorvastatin exerts additional beneficial effects on the metabolism of apo B containing lipoproteins unrelated to an increase in LDL receptor activity. Fenofibrate but not atorvastatin increases apo AI production and plasma turnover.

Authors+Show Affiliations

Division of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital Basel, Basel, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14523053

Citation

Bilz, Stefan, et al. "Effects of Atorvastatin Versus Fenofibrate On apoB-100 and apoA-I Kinetics in Mixed Hyperlipidemia." Journal of Lipid Research, vol. 45, no. 1, 2004, pp. 174-85.
Bilz S, Wagner S, Schmitz M, et al. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res. 2004;45(1):174-85.
Bilz, S., Wagner, S., Schmitz, M., Bedynek, A., Keller, U., & Demant, T. (2004). Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. Journal of Lipid Research, 45(1), 174-85.
Bilz S, et al. Effects of Atorvastatin Versus Fenofibrate On apoB-100 and apoA-I Kinetics in Mixed Hyperlipidemia. J Lipid Res. 2004;45(1):174-85. PubMed PMID: 14523053.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. AU - Bilz,Stefan, AU - Wagner,Stephan, AU - Schmitz,Michaela, AU - Bedynek,Andrea, AU - Keller,Ulrich, AU - Demant,Thomas, Y1 - 2003/10/01/ PY - 2003/10/3/pubmed PY - 2004/9/4/medline PY - 2003/10/3/entrez SP - 174 EP - 85 JF - Journal of lipid research JO - J Lipid Res VL - 45 IS - 1 N2 - Kinetics of apo B and apo AI were assessed in 8 patients with mixed hyperlipidemia at baseline and after 8 weeks of atorvastatin 80 mg q.d. and micronised fenofibrate 200 mg q.d. in a cross-over study. Both increased hepatic production and decreased catabolism of VLDL accounted for elevated cholesterol and triglyceride concentrations at baseline. Atorvastatin significantly decreased triglyceride, total, VLDL and LDL cholesterol and apo B concentrations (-65%, -36%, -57%, -40% and -33%, respectively, P<0.05). Kinetic analysis revealed that atorvastatin stimulated the catabolism of apo B containing lipoproteins, enhanced the delipidation of VLDL1 and decreased VLDL1 production. Fenofibrate lowered triglycerides and VLDL cholesterol (-57% and -64%, respectively, P<0.05) due to enhanced delipidation of VLDL1 and VLDL2 and increased VLDL1 catabolism. Changes of HDL particle composition accounted for the increase of HDL cholesterol during atorvastatin and fenofibrate (18% and 23%, P<0.01). Only fenofibrate increased apo AI concentrations through enhanced apo AI synthesis (45%, P<0.05). We conclude that atorvastatin exerts additional beneficial effects on the metabolism of apo B containing lipoproteins unrelated to an increase in LDL receptor activity. Fenofibrate but not atorvastatin increases apo AI production and plasma turnover. SN - 0022-2275 UR - https://www.unboundmedicine.com/medline/citation/14523053/Effects_of_atorvastatin_versus_fenofibrate_on_apoB_100_and_apoA_I_kinetics_in_mixed_hyperlipidemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-2275(20)31934-9 DB - PRIME DP - Unbound Medicine ER -